{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:24:32Z","timestamp":1791566672284,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00256-025-04976-5","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:46:12Z","timestamp":1750434372000},"page":"2481-2488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent developments in pharmacologic therapy of synovitis in osteoarthritis"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-7815","authenticated-orcid":false,"given":"Francis","family":"Berenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"4976_CR1","unstructured":"Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, et al. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol [Internet]. 2023 Sep 1;5(9):e508\u201322."},{"issue":"7798","key":"4976_CR2","first-page":"638","volume":"342","author":"E N\u00fcesch","year":"2011","unstructured":"N\u00fcesch E, Dieppe P, Reichenbach S, Williams S, Iff S, J\u00fcni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: Population based cohort study. BMJ. 2011;342(7798):638.","journal-title":"BMJ"},{"issue":"3","key":"4976_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","volume":"22","author":"TE McAlindon","year":"2014","unstructured":"McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363.","journal-title":"Osteoarthritis Cartilage"},{"key":"4976_CR4","doi-asserted-by":"crossref","unstructured":"Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open [Internet]. 2012;2(1).","DOI":"10.1136\/bmjopen-2011-000435"},{"key":"4976_CR5","unstructured":"Fda, Cder, Mccrayk. Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment Guidance for Industry DRAFT GUIDANCE. Available from: https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"issue":"3","key":"4976_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1148\/radiol.14140991","volume":"274","author":"FW Roemer","year":"2015","unstructured":"Roemer FW, Kwoh CK, Hannon MJ, Hunter DJ, Eckstein F, Wang Z, et al. Can structural joint damage measured with mr imaging be used to predict knee replacement in the following year? Radiology. 2015;274(3):810\u201320.","journal-title":"Radiology"},{"key":"4976_CR7","doi-asserted-by":"crossref","unstructured":"Roemer FW, Kent Kwoh C, Hannon MJ, Hunter DJ, Eckstein F, Fujii T, et al. What comes first? Multitissue involvement leading to radiographic osteoarthritis: magnetic resonance imaging-based trajectory analysis over four years in the osteoarthritis initiative. Arthritis Rheumatol [Internet]. 2015 Aug 1;67(8):2085\u201396.","DOI":"10.1002\/art.39176"},{"issue":"10","key":"4976_CR8","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/art.39731","volume":"68","author":"JE Collins","year":"2016","unstructured":"Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium. Arthritis and Rheumatology. 2016;68(10):2422\u201331.","journal-title":"Arthritis and Rheumatology"},{"key":"4976_CR9","doi-asserted-by":"crossref","unstructured":"MacFarlane LA, Yang H, Collins JE, Jarraya M, Guermazi A, Mandl LA, et al. Association of Changes in Effusion-Synovitis With Progression of Cartilage Damage Over Eighteen Months in Patients With Osteoarthritis and Meniscal Tear. Arthritis Rheumatol [Internet]. 2019 Jan 1;71(1):73\u201381.","DOI":"10.1002\/art.40660"},{"issue":"5","key":"4976_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.joca.2005.01.005","volume":"13","author":"X Ayral","year":"2005","unstructured":"Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: A potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - Results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage. 2005;13(5):361\u20137.","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"4976_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/annrheumdis-2014-205894","volume":"75","author":"I Atukorala","year":"2016","unstructured":"Atukorala I, Kwoh CK, Guermazi A, Roemer FW, Boudreau RM, Hannon MJ, et al. Synovitis in knee osteoarthritis: A precursor of disease? Ann Rheum Dis. 2016;75(2):390\u20135.","journal-title":"Ann Rheum Dis"},{"key":"4976_CR12","doi-asserted-by":"crossref","unstructured":"Moulin D, Sellam J, Berenbaum F, Guicheux J, Boutet MA. The role of the immune system in osteoarthritis: mechanisms, challenges and future directions. Nat Rev Rheumatol. 2025;21(4):221\u2013236.","DOI":"10.1038\/s41584-025-01223-y"},{"key":"4976_CR13","doi-asserted-by":"crossref","unstructured":"Deng Z, Yang W, Zhao B, Yang Z, Li D, Yang F. Advances in Research on M1\/M2 Macrophage Polarization in the Pathogenesis and Treatment of Osteoarthritis. Heliyon [Internet]. 2025 Feb;e42881.","DOI":"10.1016\/j.heliyon.2025.e42881"},{"issue":"11","key":"4976_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.joca.2014.12.007","volume":"23","author":"C Deligne","year":"2015","unstructured":"Deligne C, Casulli S, Pigenet A, Bougault C, Campillo-Gimenez L, Nourissat G, et al. Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. Osteoarthritis Cartilage. 2015;23(11):1843.","journal-title":"Osteoarthritis Cartilage"},{"key":"4976_CR15","doi-asserted-by":"crossref","unstructured":"Binvignat M, Sokol H, Mariotti-Ferrandiz E, Berenbaum F, Sellam J. Osteoarthritis and gut microbiome. Joint Bone Spine [Internet]. 2021 Oct 1;88(5).","DOI":"10.1016\/j.jbspin.2021.105203"},{"key":"4976_CR16","doi-asserted-by":"crossref","unstructured":"Kortekaas MC, Kwok WY, Reijnierse M, Stijnen T, Kloppenburg M. Brief Report: Association of Inflammation With Development of Erosions in Patients With Hand Osteoarthritis: A Prospective Ultrasonography Study. Arthritis & Rheumatology [Internet]. 2016 Feb 1;68(2):392\u20137.","DOI":"10.1002\/art.39438"},{"key":"4976_CR17","doi-asserted-by":"crossref","unstructured":"Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis [Internet]. 2018\/10\/05. 2018;77(12):1757\u201364.","DOI":"10.1136\/annrheumdis-2018-213202"},{"key":"4976_CR18","doi-asserted-by":"crossref","unstructured":"Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis [Internet]. 2014\/05\/13. 2015;74(9):1697\u2013705.","DOI":"10.1136\/annrheumdis-2014-205348"},{"issue":"6","key":"4976_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/ard.2011.149849","volume":"71","author":"G Verbruggen","year":"2012","unstructured":"Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: A double blind, randomised trial on structure modification. Ann Rheum Dis. 2012;71(6):891\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4976_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/art.24096","volume":"61","author":"X Chevalier","year":"2009","unstructured":"Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken). 2009;61(3):344\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"4976_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/art.40840","volume":"71","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, et al. A Phase II Trial of Lutikizumab, an Anti\u2013Interleukin-1\u03b1\/\u03b2 Dual Variable Domain Immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 2019;71(7):1056\u201369.","journal-title":"Arthritis Rheumatol"},{"key":"4976_CR22","doi-asserted-by":"crossref","unstructured":"Kloppenburg M, Peterfy C, Haugen IK, Kroon F, Chen S, Wang L, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1alpha and anti-interleukin-1beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis [Internet]. 2018\/12\/16. 2019;78(3):413\u201320.","DOI":"10.1136\/annrheumdis-2018-213336"},{"key":"4976_CR23","doi-asserted-by":"crossref","unstructured":"Schieker M, Conaghan PG, Mindeholm L, Praestgaard J, Solomon DH, Scotti C, et al. Effects of Interleukin-1\u03b2 Inhibition on Incident Hip and Knee Replacement\u202f: Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med [Internet]. 2020 Oct 6;173(7):509\u201315.","DOI":"10.7326\/M20-0527"},{"key":"4976_CR24","doi-asserted-by":"crossref","unstructured":"De la Vega RE, Sellon JL, Smith J, Wisniewski SJ, Jurisson ML, Frick MA, et al. A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint. Sci Transl Med [Internet]. 2025 Jun 4;17(801).","DOI":"10.1126\/scitranslmed.adu9804"},{"key":"4976_CR25","unstructured":"Study Details | Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05835895?term=Sc-rAAV2.5IL-1Ra&rank=2"},{"key":"4976_CR26","doi-asserted-by":"crossref","unstructured":"Senter R, Boyce R, Repic M, Martin EW, Chabicovsky M, Langevin-Carpentier G, et al. Efficacy and Safety of FX201, a Novel Intra-Articular IL-1Ra Gene Therapy for Osteoarthritis Treatment, in a Rat Model. Hum Gene Ther [Internet]. 2022 May 1;33(9\u201310):541\u20139.","DOI":"10.1089\/hum.2021.131"},{"key":"4976_CR27","doi-asserted-by":"crossref","unstructured":"Latourte A, Cherifi C, Maillet J, Ea HK, Bouaziz W, Funck-Brentano T, et al. Systemic inhibition of IL-6\/Stat3 signalling protects against experimental osteoarthritis. Ann Rheum Dis [Internet]. 2017 Apr 1;76(4):748\u201355.","DOI":"10.1136\/annrheumdis-2016-209757"},{"key":"4976_CR28","doi-asserted-by":"crossref","unstructured":"Richette P, Latourte A, Sellam J, Wendling D, Piperno M, Goupille P, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis [Internet]. 2021 Mar 1;80(3):349\u201355.","DOI":"10.1136\/annrheumdis-2020-218547"},{"key":"4976_CR29","unstructured":"Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients - ACR Meeting Abstracts [Internet]. Available from: https:\/\/acrabstracts.org\/abstract\/safety-and-immunogenicity-of-an-active-anti-il-6-immunotherapy-in-a-phase-1-clinical-trial-in-knee-osteoarthritis-patients\/"},{"key":"4976_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu D, Vithran DTA, Kwabena BR, Xiao W, Li Y. CC chemokines and receptors in osteoarthritis: new insights and potential targets. Arthritis Res Ther [Internet]. 2023 Dec 1;25(1):1\u201311.","DOI":"10.1186\/s13075-023-03096-6"},{"key":"4976_CR31","doi-asserted-by":"crossref","unstructured":"Nijjar JS, Abbott-Banner K, Ray R, Vicente SM, Bentley JH, Muya C, et al. OP0075\u2005Efficacy, safety, pharmacokinetics and immunogenicity of repeated dosing of GSK3858279 in patients with knee osteoarthritis: a phase 1, randomized, double-blind, placebo-controlled study. Ann Rheum Dis [Internet]. 2023 Jun 1;82(Suppl 1):51\u20132. Available from: https:\/\/ard.bmj.com\/content\/82\/Suppl_1\/51","DOI":"10.1136\/annrheumdis-2023-eular.751"},{"issue":"1","key":"4976_CR32","first-page":"43","volume":"5","author":"F Berenbaum","year":"1994","unstructured":"Berenbaum F, Rajzbaum G, Amor B, Toubert A. Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur Cytokine Netw. 1994;5(1):43.","journal-title":"Eur Cytokine Netw"},{"issue":"10","key":"4976_CR33","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1016\/S2665-9913(20)30171-5","volume":"2","author":"G Schett","year":"2020","unstructured":"Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes S, Griep E, et al. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial. Lancet Rheumatol. 2020;2(10):e623\u201332.","journal-title":"Lancet Rheumatol"},{"key":"4976_CR34","doi-asserted-by":"crossref","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage [Internet]. 2019 Nov 1;27(11):1578\u201389.","DOI":"10.1016\/j.joca.2019.06.011"},{"key":"4976_CR35","doi-asserted-by":"crossref","unstructured":"Wang Y, Jones G, Keen HI, Hill CL, Wluka AE, Kasza J, et al. Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial. The Lancet [Internet]. 2023 Nov 11;402(10414):1764\u201372.","DOI":"10.1016\/S0140-6736(23)01572-6"},{"key":"4976_CR36","doi-asserted-by":"crossref","unstructured":"Zhu Z, Yu Q, Leng X, Xu J, Ren L, Wang K, et al. Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial. JAMA Intern Med [Internet]. 2025 Jun 2.","DOI":"10.1001\/jamainternmed.2025.1359"},{"key":"4976_CR37","doi-asserted-by":"crossref","unstructured":"Kingsbury SR, Tharmanathan P, Keding A, Ronaldson SJ, Grainger A, Wakefield RJ, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis a randomized trial. Ann Intern Med [Internet]. 2018 Mar 20;168(6):385\u201395.","DOI":"10.7326\/M17-1430"},{"issue":"4","key":"4976_CR38","doi-asserted-by":"publisher","first-page":"105198","DOI":"10.1016\/j.jbspin.2021.105198","volume":"88","author":"A Najm","year":"2021","unstructured":"Najm A, Alunno A, Gwinnutt JM, Weill C, Berenbaum F. Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Joint Bone Spine. 2021;88(4):105198.","journal-title":"Joint Bone Spine"},{"key":"4976_CR39","doi-asserted-by":"crossref","unstructured":"Malone A, Kowalski MM, Helliwell J, Lynggaard Boll S, Rovsing H, Moriat K, et al. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial. Lancet Rheumatol [Internet]. 2024 Dec 1;6(12).","DOI":"10.1016\/S2665-9913(24)00223-6"},{"key":"4976_CR40","doi-asserted-by":"crossref","unstructured":"Hunter DJ, Chang CC, Wei JCC, Lin HY, Brown C, Tai TT, et al. TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study. Arthritis Res Ther [Internet]. 2022 Dec 1;24(1):1\u201311.","DOI":"10.1186\/s13075-022-02739-4"},{"key":"4976_CR41","unstructured":"A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks - ACR Meeting Abstracts [Internet]. Available from: https:\/\/acrabstracts.org\/abstract\/a-phase-3-study-of-repeat-injection-of-tlc599-in-osteoarthritis-of-the-knee-benefits-to-52-weeks\/"},{"key":"4976_CR42","doi-asserted-by":"crossref","unstructured":"Kroon FPB, Kortekaas MC, Boonen A, B\u00f6hringer S, Reijnierse M, Rosendaal FR, et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. The Lancet [Internet]. 2019 Nov 30;394(10213):1993\u20132001.","DOI":"10.1016\/S0140-6736(19)32489-4"},{"key":"4976_CR43","doi-asserted-by":"crossref","unstructured":"Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage [Internet]. 2018;26(1):18\u201327.","DOI":"10.1016\/j.joca.2017.08.015"},{"key":"4976_CR44","doi-asserted-by":"crossref","unstructured":"Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, et al. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis and Rheumatology [Internet]. 2020 Oct 1;72(10):1694\u2013706.","DOI":"10.1002\/art.41315"},{"key":"4976_CR45","unstructured":"A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants - ACR Meeting Abstracts [Internet]. Available from: https:\/\/acrabstracts.org\/abstract\/a-phase-3-56-week-multicenter-randomized-double-blind-placebo-controlled-trial-oa-11-to-evaluate-the-efficacy-and-safety-of-a-single-injection-of-lorecivivint-injected-in-the-target-knee-joint\/"},{"key":"4976_CR46","doi-asserted-by":"crossref","unstructured":"Wittoek R, Verbruggen G, Vanhaverbeke T, Colman R, Elewaut D. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial. Nat Med [Internet]. 2024 Mar 1;30(3):829\u201336.","DOI":"10.1038\/s41591-024-02822-0"},{"key":"4976_CR47","doi-asserted-by":"crossref","unstructured":"Grigsby E, Rickam M, Thewlis D, Simon L, Chavez R, Huston M, et al. XT-150- A novel immunomodulatory gene therapy for osteoarthritis pain in phase 2b development. Osteoarthritis Cartilage [Internet]. 2021 Sep 1;29:S12. Available from: http:\/\/www.oarsijournal.com\/article\/S1063458421007548\/fulltext","DOI":"10.1016\/j.joca.2021.05.023"},{"key":"4976_CR48","doi-asserted-by":"crossref","unstructured":"Rutman H, McBride M, Grigsby EJ, Kapural L, Collins S, Glover DK, et al. Efficacy of xt-150, a novel non-viral gene therapy delivering il-10v, on moderate to severe pain due to knee osteoarthritis: patient subgroup analysis. Osteoarthritis Cartilage [Internet]. 2024 Apr 1;32:S41. Available from: http:\/\/www.oarsijournal.com\/article\/S1063458424001067\/fulltext","DOI":"10.1016\/j.joca.2024.02.061"},{"key":"4976_CR49","doi-asserted-by":"crossref","unstructured":"Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest [Internet]. 2017\/12\/05. 2017;127(12):4217\u201327.","DOI":"10.1172\/JCI97233"},{"key":"4976_CR50","doi-asserted-by":"crossref","unstructured":"Bliddal H, Bays H, Czernichow S, Udd\u00e9n Hemmingsson J, Hjelmes\u00e6th J, Hoffmann Morville T, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med [Internet]. 2024 Oct 31;391(17):1573\u201383.","DOI":"10.1056\/NEJMoa2403664"},{"key":"4976_CR51","first-page":"182","volume":"1","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022;1:182.","journal-title":"Pharmacol Res"},{"key":"4976_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","volume":"32","author":"C Meurot","year":"2022","unstructured":"Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R, et al. Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity? J Orthop Translat. 2022;32:121\u20139.","journal-title":"J Orthop Translat"},{"issue":"1","key":"4976_CR53","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022;12(1):1567.","journal-title":"Sci Rep"},{"key":"4976_CR54","doi-asserted-by":"crossref","unstructured":"Ramirez-Perez S, Reyes-Perez IV, Martinez-Fernandez DE, Hernandez-Palma LA, Bhattaram P. Targeting inflammasome-dependent mechanisms as an emerging pharmacological approach for osteoarthritis therapy. iScience. 2022 Nov 11;25(12):105548.","DOI":"10.1016\/j.isci.2022.105548"},{"key":"4976_CR55","unstructured":"Study Details | Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04886258?cond=Osteoarthritis&intr=DFV890&rank=1"},{"key":"4976_CR56","unstructured":"Study Details | Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01768975"},{"key":"4976_CR57","doi-asserted-by":"crossref","unstructured":"Damerau A, Rosenow E, Alkhoury D, Buttgereit F, Gaber T. Fibrotic pathways and fibroblast-like synoviocyte phenotypes in osteoarthritis. Front Immunol. 2024 Jun 4;15:1385006.","DOI":"10.3389\/fimmu.2024.1385006"},{"key":"4976_CR58","doi-asserted-by":"crossref","unstructured":"Henriques J, Berenbaum F, Mobasheri A. Obesity-induced fibrosis in osteoarthritis: Pathogenesis, consequences and novel therapeutic opportunities. Osteoarthr Cartil Open [Internet]. 2024 Dec;6(4):100511.","DOI":"10.1016\/j.ocarto.2024.100511"},{"key":"4976_CR59","doi-asserted-by":"crossref","unstructured":"Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, et al. CCL2\/CCR2, but not CCL5\/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis [Internet]. 2016 May 1;76(5):914.","DOI":"10.1136\/annrheumdis-2016-210426"},{"key":"4976_CR60","doi-asserted-by":"crossref","unstructured":"Longobardi L, Temple JD, Tagliafierro L, Willcockson H, Esposito A, D\u2019Onofrio N, et al. Role of the C-C chemokine receptor-2 in a murine model of injury-induced osteoarthritis. Osteoarthritis Cartilage [Internet]. 2017 Jun 1;25(6):914\u201325.","DOI":"10.1016\/j.joca.2016.11.004"},{"key":"4976_CR61","doi-asserted-by":"crossref","unstructured":"Dell\u2019Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One [Internet]. 2018 Jan 1;13(1).","DOI":"10.1371\/journal.pone.0191045"},{"issue":"5","key":"4976_CR62","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/annrheumdis-2021-221763","volume":"81","author":"F Angelini","year":"2022","unstructured":"Angelini F, Widera P, Mobasheri A, Blair J, Struglics A, Uebelhoer M, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022;81(5):666\u201375.","journal-title":"Ann Rheum Dis"},{"key":"4976_CR63","doi-asserted-by":"crossref","unstructured":"Mobasheri A, Loeser R. Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development. Nature Reviews Rheumatology 2024 20:9 [Internet]. 2024 May 17;20(9):525\u20136.","DOI":"10.1038\/s41584-024-01126-4"},{"key":"4976_CR64","doi-asserted-by":"crossref","unstructured":"Berenbaum F. Perspective: Empowering Osteoarthritis Drug Development through Assessment of Synovitis by CE-MRI: A New Approach in Clinical Trials. Osteoarthritis Imaging [Internet]. 2024 Dec 20;100259.","DOI":"10.1016\/j.ostima.2024.100259"}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-025-04976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-025-04976-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-025-04976-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:32:48Z","timestamp":1758706368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-025-04976-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4976"],"URL":"https:\/\/doi.org\/10.1007\/s00256-025-04976-5","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"value":"0364-2348","type":"print"},{"value":"1432-2161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Francis Berenbaum is the CEO of 4Moving Biotech. 4Moving Biotech and Sorbonne University own two patents for the method of use of GLP1 analogs in the treatment of osteoarthritis (PCT\/FR2013\/051998 and PCT\/IB2018\/\/059100).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}